The U.S. Food and Drug Administration has approved dupilumab (Dupixent), developed jointly by Regeneron Pharmaceuticals and Sanofi, for the treatment of allergic fungal rhinosinusitis (AFRS) in patients aged six years and older who have undergone prior sino-nasal surgery. The approval marks the ninth indication for the blockbuster therapeutic, which addresses inflammatory conditions driven by type 2 immune responses.
The authorization was supported by Phase 3 clinical trial data demonstrating the drug's effectiveness in reducing nasal symptoms and decreasing the need for systemic corticosteroid treatment or additional surgical intervention. AFRS is a chronic inflammatory sinus condition that develops when the immune system responds abnormally to fungal colonization in the nasal cavity, often requiring multiple surgical procedures to manage.
Dupixent's expanding label reflects sustained clinical demand in the type 2 inflammation therapeutic space, where the monoclonal antibody has established significant market presence. Market reaction to the approval was modest, with Regeneron shares declining 0.77% on the announcement and trading below key technical support levels at the time of publication.